Table 1 Patient characteristics prior matching
Parameter | CyberKnife (n = 104) | VMAT (n = 38) | p Value |
|---|---|---|---|
Age (years) | 68.9 ± 7.3 | 72.5 ± 6.1 | 0.0069 |
Risk group | 0.72 | ||
Low | 10 (10%) | 4 (11%) | |
Intermediate | 60 (57%) | 19 (50%) | |
High | 34 (33%) | 15 (40%) | |
Neoadjuvant ADT | 95 (91%) | 34 (90%) | 0.75 |
Duration of neoadjuvant ADT (months) | 8.3 ± 11.1 | 6.3 ± 0.9 | 0.29 |
Comorbidity | |||
Antithrombotic therapy | 13 (13%) | 6 (16%) | 0.59 |
Diabetes | 14 (14%) | 6 (16%) | 0.79 |
Previous TURP | 2 (2%) | 1 (3%) | 0.99 |
Medication to improve dysuria at baseline | 17 (16.3%) | 7 (18.4%) | 0.8 |
Pre-treatment IPSS | 0.96 | ||
Mild (0–7) | 33 (32%) | 13 (34%) | |
Moderate (8–19) | 59 (57%) | 21 (55%) | |
Severe (20–35) | 11 (11%) | 4 (11%) | |
Prostate volume (cc) | 25.9 ± 9.6 | 26.0 ± 15.3 | 0.97 |